Clinical effect of MUC1 and its relevance to BRAF V600E mutation in papillary thyroid carcinoma: a case-control study

• Published in: Cancer management and research Vol. 10; pp. 1351 - 1358
• Main Authors: Li, Quan, Jin, Wen-Xu, Jin, Yi-Xiang, Zheng, Zhou-Ci, Zhou, Xiao-Fen, Wang, Qing-Xuan, Ye, Dan-Rong, Sun, Yi-Han, Zhang, Xiao-Hua, Wang, Ou-Chen, Chen, En-Dong, Cai, Ye-Feng
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2018; Taylor & Francis Ltd; Dove Medical Press
• Subjects: BRAF mutation; Breast cancer; Cancer genetics; Cancer metastasis; Cancer patients; Carcinoma; Elderly patients; extrathyroid extension; Gene mutation; Genomes; Genomics; Health aspects; Kinases; lymph node metastasis; MUC1; Mucins; Mutation; Original Research; papillary thyroid cancer; prognosis; Thyroid cancer; Thyroid diseases; United States > US; MUC1; prognosis; papillary thyroid cancer; extrathyroid extension; BRAF mutation; lymph node metastasis
• ISSN: 1179-1322; 1179-1322
• DOI: 10.2147/CMAR.S161501

To investigate the clinical effects of on papillary thyroid cancer (PTC) and explore the relationship between expression and mutation. The data of 69 patients subjected to fine-needle aspiration biopsy in our hospital and 486 patient data downloaded from The Cancer Genome Atlas (TCGA) database were used. Univariate and multivariate analyses were performed. The results on the 486 patients recorded in the TCGA indicated that high expression was independently related to mutation, lymph node metastasis (LNM), and unifocal type. In the 69 fine-needle aspiration biopsy patients with PTC, high expression was significantly related to LNM and extrathyroid extension (ETE). The result of Pearson's correlation coefficient showed that mutation and expression were moderately correlated. Moreover, in the subgroup with low expression, the patients with mutation had higher ETE frequency and LNM than those without mutation. In the subgroup with mutation, patients with high expression exhibited higher ETE frequency than those with low expression, and high expression occurred in older patients. In the subgroup with wild-type mutation, patients with high expression had a higher incidence of ETE and LNM than those with low expression. We demonstrated that the is an important oncogene in PTC and may have great significance on therapeutic cancer vaccine development.